23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies

23andMe为正在进行的23ME-00610 1/2a期临床试验提供有关晚期实体恶性肿瘤患者的疗效，安全性和剂量选择的数据

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, an investigational antibody targeting CD200R1, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA, taking place November 1-5, 2023..

加利福尼亚州南旧金山市，2023年9月27日（GLOBE NEWSWIRE）-23andMe Holding Co.（纳斯达克股票代码：ME）（“23andMe”），一家领先的人类遗传学和生物制药公司，今天宣布两张海报发表于23ME-00610，一种针对CD200R1的研究性抗体，于2023年11月1日至5日在加利福尼亚州圣地亚哥举行的癌症免疫治疗学会（SITC）第38届年会上。。

The presentations will include updated safety and efficacy data from the Phase 1 portion of the ongoing Phase 1/2a study of 23ME-00610 in patients with advanced solid malignancies. The Company will also present data on the pharmacokinetics, pharmacodynamics and safety data supporting the Phase 1 and Phase 2 dose selection for the 23ME-00610 study..

这些报告将包括来自23ME-00610正在进行的23ME-00610期1/2a期研究的第1阶段的最新安全性和有效性数据，用于晚期实体恶性肿瘤患者。该公司还将提供有关药代动力学，药效学和安全性数据的数据，以支持23ME-00610研究的1期和2期剂量选择。。

Title:First-in-Class anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced

题目：晚期患者的一流抗CD200R1抗体23ME-00610

Solid Malignancies: Updated Phase 1 Results

实体恶性肿瘤：更新的第一阶段结果

Session: Annual Meeting Regular Poster Abstract Presenter

会议：年会定期海报摘要主持人

Abstract/Poster Number: 619

摘要/海报编号：619

Location: Posters are presented in Exhibit Halls A and B1 (poster will also be available to view under the investors section of the Company’s website at investors.23andme.com).

地点：海报在展览厅A和B1中展示（海报也可以在公司网站的投资者部分在investors.23andme.com上查看）。

Date and Time: Friday, Nov. 3, 2023; Poster Hall Hours: 9 a.m.–7 p.m. PT

日期和时间：2023年11月3日星期五；海报厅时间：上午9点至下午7点

Title:Phase 1/2a Dose Selection of 23ME-00610, a First-in-Class anti-CD200R1 Antibody, in

题目：第一类抗CD200R1抗体23ME-00610的1/2a期剂量选择

Patients with Advanced Solid Malignancies

晚期实体恶性肿瘤患者

Session: Annual Meeting Regular Poster Abstract Presenter

会议：年会定期海报摘要主持人

Abstract/Poster Number: 609

摘要/海报编号：609

Location: Posters are presented in Exhibit Halls A and B1 (poster will also be available to view under the investors section of the Company’s website at investors.23andme.com).

地点：海报在展览厅A和B1中展示（海报也可以在公司网站的投资者部分在investors.23andme.com上查看）。

Date and Time: Friday, Nov. 3, 2023; Poster Hall Hours: 9 a.m.–7 p.m. PT

日期和时间：2023年11月3日星期五；海报厅时间：上午9点至下午7点

About 23ME-00610

大约23ME-00610

23ME-00610 is a high-affinity, fully humanized monoclonal antibody that is designed to bind to CD200R1 and prevent the interaction of CD200R1 with CD200. The CD200–CD200R1 axis is an immunological checkpoint that plays a pivotal role in maintenance of immune tolerance. CD200R1 is an inhibitory receptor expressed on T cells and myeloid cells while CD200, the ligand for CD200R1, is highly expressed on certain tumors.

23ME-00610是一种高亲和力，完全人源化的单克隆抗体，旨在与CD200R1结合并阻止CD200R1与CD200的相互作用。CD200–CD200R1轴是一个免疫检查点，在维持免疫耐受中起关键作用。CD200R1是在T细胞和骨髓细胞上表达的抑制性受体，而CD200R1的配体CD200在某些肿瘤上高度表达。

In preclinical studies, binding of tumor-associated CD200 to CD200R1 leads to immune suppression and decreased immune cell killing of cancer cells. Preclinical data indicate that this mechanism has the potential to restore the ability for both T-cells and myeloid cells to kill cancer cells. Clinical trials registry (clinicaltrials.gov): NCT05199272..

在临床前研究中，肿瘤相关CD200与CD200R1的结合导致免疫抑制并降低癌细胞的免疫细胞杀伤。临床前数据表明，这种机制有可能恢复T细胞和骨髓细胞杀死癌细胞的能力。临床试验注册处（clinicaltrials.gov）：NCT05199272。。

About 23andMe

大约23andMe

23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visit www.23andMe.com.

23andMe是一家由遗传学领导的消费者医疗保健和生物制药公司，致力于健康的未来。欲了解更多信息，请访问www.23andMe.com。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform.

本新闻稿包含1933年“证券法”第27A条（经修订）和1934年“证券交易所法”第21E条（经修订）含义内的前瞻性声明，包括但不限于，关于23andMe业务在消费者遗传学和治疗学方面的未来表现以及其专有研究平台的发展和潜力的声明。

All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s products, strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, potential future collaborations, therapeutics development, product development and launches, the successful commercialization and market acceptance of new products and objectives of management, are forward-looking statements.

除历史事实陈述外，本新闻稿包括或纳入的所有陈述，包括有关23andMe产品，战略，财务状况，持续经营资金，现金储备，预计成本，计划，未来潜在合作，治疗开发，产品开发和发布，新产品的成功商业化和市场接受以及管理目标是前瞻性陈述。

The words 'believes,' 'anticipates,' 'estimates,' 'plans,' 'expects,' 'intends,' 'may,' 'could,' 'should,' 'potential,' 'likely,' 'projects,' “predicts,” 'continue,' 'will,' “schedule,” and 'would' or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

“相信”，“预期”，“估计”，“计划”，“期望”，“意图”，“可能”，“应该”，“潜力”，“可能”，“项目”，“预测“，”继续“，”计划“和”将“或在每种情况下，它们的否定或其他变体或可比较的术语旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别词。

These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements.

这些前瞻性陈述是基于23andMe当前对未来事件和各种假设的预期和预测的预测。23andMe不能保证它能真正实现其前瞻性陈述中披露的计划，意图或期望，您不应过分依赖23andMe的前瞻性陈述。

These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other.

这些前瞻性陈述涉及许多风险，不确定性（其中许多是23andMe无法控制的）或其他。

Contacts:

联络：

Investor Relations Contact: investors@23andMe.com

投资者关系联系人：investors@23andMe.com

Media Contact: press@23andMe.com

Media Contact: press@23andMe.com